

Conflict-of-interest statement

Title:

Telbivudine versus tenofovir in HBeAg-negative chronic hepatitis B patients: OPTIMA roadmap study

Authors:

Zahari Krastev, Diana Petrova, Iskren Kotzev, Celen Mustafa Kemal, Kamal Hamed, Richa Chandra

Krastev Z received fees for serving as a member of advisory board of Gilead, as well as research funding from Receptos, Centocor, Millennium Pharmaceuticals, Gilead, Abbvie, MSD, GSK, Roche, Novartis, Johnson & Johnson, Idenix, Norgine, Applied Clinical Pharmacology Services, Comac Medical, and Schwabe.


Petrova D received research funding from Centocor, Gilead, GSK, Roche, Novartis, Johnson & Johnson, Idenix, Norgine, and Aventis.

Kotzev I received lecture fees from Novartis.

Kemal CM has nothing to declare.

Hamed K and Chandra R are employees of Novartis Pharmaceuticals Corporation.

Corresponding author:



Dr Richa Chandra,

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA

14 March 2016,